HDAC9 and ovarian carcinoma: Recently, researchers have synthesized several platinum(IV) complexes derived from cisplatin with various histone deacetylase (HDAC) inhibitor axial ligands and found that these compounds can exhibit higher anti-cancer activity than the platinum(II) drug including in cisplatin-sensitive and -resistant ovarian cancer cell lines [6, 7].